Nektar Therapeutics
NKTR
$73.32
-$2.12-2.81%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -9.34% | 3.83% | -25.25% | -51.13% | -52.42% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -9.34% | 3.83% | -25.25% | -51.13% | -52.42% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -9.34% | 3.83% | 2.87% | -40.12% | -18.72% |
| SG&A Expenses | -25.23% | -44.80% | -34.72% | -15.23% | -16.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.51% | -10.41% | -24.06% | -25.85% | -21.70% |
| Operating Income | -16.71% | 13.77% | 22.66% | 8.07% | 1.92% |
| Income Before Tax | 2.78% | 11.78% | -614.82% | 4.03% | 20.14% |
| Income Tax Expenses | 101.06% | 23.08% | 111.97% | -466.67% | -508.70% |
| Earnings from Continuing Operations | 2.33% | 11.75% | -596.89% | 4.14% | 20.57% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.33% | 11.75% | -596.89% | 4.14% | 20.57% |
| EBIT | -16.71% | 13.77% | 22.66% | 8.07% | 1.92% |
| EBITDA | -16.98% | 13.27% | 22.38% | 5.91% | -1.55% |
| EPS Basic | 58.38% | 49.83% | -442.31% | 29.42% | 21.50% |
| Normalized Basic EPS | 58.71% | 50.58% | 40.91% | 29.53% | -4.66% |
| EPS Diluted | 58.38% | 49.83% | -448.62% | 29.42% | 21.50% |
| Normalized Diluted EPS | 58.71% | 50.58% | 39.82% | 29.53% | -4.66% |
| Average Basic Shares Outstanding | 134.64% | 75.89% | 45.16% | 35.82% | 1.19% |
| Average Diluted Shares Outstanding | 134.64% | 75.89% | 42.54% | 35.82% | 1.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |